Navigation Links
Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder
Date:11/1/2008

First Clinical Study of Paliperidone ER in this Under-Studied Condition

SAN DIEGO, Nov. 1 /PRNewswire/ -- Patients with schizoaffective disorder receiving paliperidone extended release tablets (paliperidone ER) for six weeks showed a significant improvement in their symptoms, according to a new study presented today at the U.S. Psychiatric & Mental Health Congress in San Diego, Calif.(1) In addition, safety findings were similar to published studies of paliperidone ER in the treatment of schizophrenia.(2)(3)

"Schizoaffective disorder is an under studied condition that despite being common among patients with serious mental illness, has no approved treatment," said Husseini Manji, M.D., Vice President, Central Nervous System and Pain, Johnson & Johnson Pharmaceutical Research and Development. "This new study suggests that paliperidone ER could be an effective option for the treatment of schizoaffective disorder. Additional studies are needed to confirm this finding."

Schizoaffective disorder is a condition, which encompasses the symptoms of both schizophrenia and a major mood disorder. Patients with schizoaffective disorder experience the psychosis characteristic of schizophrenia, such as hallucinations or delusions, as well as symptoms of mania and/or depression.(4) Schizoaffective disorder can be difficult to distinguish from schizophrenia or bipolar disorder because the symptoms are similar to both. The disorder is about one third as common as schizophrenia(5) but within those people that frequently use mental health services, schizophrenia and schizoaffective disorder may account for approximately 32% and 24% of cases respectively.(6)

In the 6 week, international, randomized, double-blind, placebo controlled study, 316 patients with an established diagnosis of schizoaffective disorder, who were experiencing acute symptoms, received either 6mg/day or 12mg/day paliperidone ER, or a placebo. Dosages could be reduced to 3mg/day or 9mg
'/>"/>

SOURCE Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals,Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients
2. New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients
3. New International Study Shows Women With Symptomatic Fibroids Delaying Treatment Despite Substantial Burden on Quality of Life
4. Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD
5. Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
6. Grapes May Aid a Bunch of Heart Risk Factors, U-M Animal Study Finds
7. NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation
8. Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference
9. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
10. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
11. Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...DGE, N.J., Nov. 25 Regado Bioscien...ent of antithrombotic aptamers with active control...President, will be presenting at the Piper Jaffray...k Palace Hotel in New York City. Dr. Mazzo,s pres... December 1 and will include an overview of the Co...
(Date:11/25/2009)...ORK, Nov. 25 Reportlinker.com anno...le in its catalogue: ,, Mammography Equipment....reportlinker.com/p0164330/Mammography-Equipment--...cidence of breast cancer in industrialized as well...encing growth in the mammography market. Globally,...
(Date:11/25/2009)...AM, Mass., Nov. 25 According to Mi...y on medical technology market intelligence, the n...ices will continue to see rapid growth over the ne.... MRG,s US Markets for Trauma Devices 2010 rep...mic over the next five years, with competitors int...
Breaking Medicine Technology:Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3This Summer is an Ideal Time for Commercial Real Estate Lease Renewal 53022 1This Summer is an Ideal Time for Commercial Real Estate Lease Renewal 53022 2This Summer is an Ideal Time for Commercial Real Estate Lease Renewal 53022 3PATH Malaria Vaccine Initiative and Crucell to test new malaria vaccine approach 53020 1PATH Malaria Vaccine Initiative and Crucell to test new malaria vaccine approach 53020 2SAFC Biosciences 28R 29 Defines Hydrolysate Components That Enhance Chinese Hamster Ovary 28CHO 29 Cell Line Protein Production 13241 1SAFC Biosciences 28R 29 Defines Hydrolysate Components That Enhance Chinese Hamster Ovary 28CHO 29 Cell Line Protein Production 13241 2SAFC Biosciences 28R 29 Defines Hydrolysate Components That Enhance Chinese Hamster Ovary 28CHO 29 Cell Line Protein Production 13241 3SAFC Biosciences 28R 29 Defines Hydrolysate Components That Enhance Chinese Hamster Ovary 28CHO 29 Cell Line Protein Production 13241 4
...IOPHARM Oncology,Inc. (NASDAQ: ZIOP), announced t...nnual International Myeloma Workshop being,held in...highlights,important advances made in the biology ...senting darinaparsin (ZIO-101) gene,expression pro...hanism of action as well as interim Phase II data ...
...CADE, lenalidomide,and dexamethasone , ,KOS, Greec...armaceuticals, Inc. (Nasdaq: MLNM) today reported ...trials of VELCADE based,therapies that showed cons...mplete response(1) (CR) rates in newly diagnosed,m...sented at the,prestigious 11th International Myelo...
Other Medicine Technology:ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data,Presented at International Myeloma Workshop 2ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data,Presented at International Myeloma Workshop 3ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data,Presented at International Myeloma Workshop 4Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 2Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 3Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 4Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 5Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 6Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 7Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 8
(Date:11/27/2009)...Nov.27/PRNewswire-USNewswire/--Consideredahighlyri...solidorgantransplantationisnowalife-savingmainstre...atheredattheWinspearOperaHouseinDallasonNov.11.Lea...celebratethe25thanniversaryofBaylorRegionalTranspl...nsplantintheUnitedStates. ,, Itwas25yearsagotha...
(Date:11/27/2009)... XenaCare Holdings has announced that it...undation, one of the largest nonprofit organizatio...th education. , Delray Be...ings, Inc. (OTCBB: XCHO), a company specializing i...r healthcare products, has announced today that is...
(Date:11/27/2009)... Multi-purpose bilingual coloring books ...se by the business community to educate - inform p... from Safety issues to Dinosuars to ABC,S and a ho...nt Louis, MO (PRWEB) November 27, 2009 -- Today&rs... toys to keep them busy any hour of the day, but o...
(Date:11/26/2009)...5 years, the number of Americans living with diabe...on in 2009 to 44.1 million in 2034. Over the same ...ising from $113 billion to $336 billion, even with...hers based at the University of Chicago report in ...ber of those with diabetes covered by Medicare wil...
(Date:11/26/2009)... Dr. David Kim of the Live Life Again Ce...Dallas , is one of a growing number of physicians ...king sites to connect with individuals who are int... morbid obesity. Dr. Kim is utilizing Facebook to ...t his practice with the community. , ...
Breaking Medicine News(10 mins):Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3
...IS, July 1 Uroplasty, Inc. (Amex:,UPI), a medical...rkets,innovative proprietary products for the trea... it was added to the Russell Microcap(R) Index whe... which remains in place for one,year, means automa...
...LIS, July 1 CoLucid Pharmaceuticals, Inc., an,inn...s for central nervous,system disorders, announced ...vestor Care Capital led the round, which included ...r develop a,unique migraine compound, COL-144, and...
... New research shows that a majori... pay higher taxes to fund increased education faci...d consumer attitudes to the recruitment of nurses ...are survey are concerned about the on-going effect...
...ELPHIA In the first study of its kind, researcher...Medicine,s Ross Koppel, Ph.D. studied how hospital...ches the right patient with the right dose of the ...tion administration errors, is flawed, and can inc...
...follow-up to research showing that psilocybin, a s... substantial spiritual effects, a Johns Hopkins te... last more than a year. , Writing in the Journa... Hopkins study published in 2006, continued to say...
...E, N.J., June 30 Janssen, Division,of Ortho-McNei... has,launched an authorized generic version of RIS...icals, L.L.C., Patriot is a subsidiary of McNeil-...RISPERDAL, which was first approved by the FDA in ...
Other Medicine News:Health News:Uroplasty Joins the Russell Microcap Index 2Health News:Uroplasty Joins the Russell Microcap Index 3Health News:CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound 2Health News:CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound 3Health News:CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound 4Health News:Education More Important Than Immigration to Solve Nursing Shortage, Research Shows 2Health News:Education More Important Than Immigration to Solve Nursing Shortage, Research Shows 3Health News:Flaws in the barcoded technology used to reduce medication administration errors identified 2Health News:Flaws in the barcoded technology used to reduce medication administration errors identified 3Health News:Flaws in the barcoded technology used to reduce medication administration errors identified 4Health News:Spiritual effects of hallucinogens persist, Johns Hopkins researchers report 2Health News:Janssen Announces Launch of Authorized Generic for RISPERDAL(R) 2Health News:Janssen Announces Launch of Authorized Generic for RISPERDAL(R) 3Health News:Janssen Announces Launch of Authorized Generic for RISPERDAL(R) 4
Sealing Mat for 384-well PCR plate
...pha unit, these new pads may be used in applicatio...essive runs may be sealed with the same pad. The M...te from sticking to the block and lid, and Microse...rformance, which means you can use as little as 50...
...pha unit, these new pads may be used in applicatio...essive runs may be sealed with the same pad. The...late from sticking to the block and lid, and Micro...performance, which means you can use as little as ...
Microseal 'M' mats
Medicine Products: